Drug-induced disease

Many reports in the literature discuss aspects of drug-induced disease or injury which do not necessarily identify particular drugs or classes of drugs and their associated adverse drug reactions.

Such references might focus on the diagnosis, clinical pathology, pharmacology, pharmacogenomics or treatment of a drug-induced diseases or injury. Or analyse drug-induced diseases in relation to particular groups of the population (the young, the elderly, gender).

This area of the literature is accommodated in the Litt database under the category ‘Drug-induced disease (General)’ with further classification under the categories: skin; cardiovascular; central nervous system; endocrine/metabolic; gastrointestinal/hepatic etc. Litt’s weekly ‘Drug updates’ for subscribers lists ‘Drug-induced disease (General)’ as a separate heading with PubMed hyperlinks to references under these categories.

Drug-induced disease (Cardiovascular)

(2026): Gallardo C+, Nurs Crit Care 31(2), e70385 [REVIEW] (drug-induced phlebitis)
(2026): Li D+, Cardiovasc Toxicol 26(4), 37 [REVIEW] (cardiac failure) (pharmacovigilance / pharmacoepidemiology)
(2026): Wang Z+, Curr Cardiol Rev Mar, Online ahead of print [REVIEW] (cardiotoxicity) (pharmacovigilance / pharmacoepidemiology)
(2026): Zhao S+, Cardiovasc Toxicol 26(6), 57 [REVIEW] (myocarditis / pericarditis) (pharmacovigilance / pharmacoepidemiology)
(2025): Gautier P+, Arch Cardiovasc Dis 118(2), 133-135 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Hoffmann P+, J Pharmacol Toxicol Methods Oct, Online ahead of print [REVIEW]
(2025): Kundnani NR+, Medicina (Kaunas) 61(4), 709 [REVIEW]
(2025): Lai J+, PLoS One Nov (e-Collection) [REVIEW] (drug-induced shock) (pharmacovigilance / pharmacoepidemiology)
(2025): Nordqvist O+, Clin Pharmacol Ther Nov, Online ahead of print (QT prolongation) (pharmacovigilance / pharmacoepidemiology)
(2025): Ren G+, BMC Pharmacol Toxicol 26(1), 27 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Ren G+, Sci Rep 15(1), 10359 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Ren G+, Front Cardiovasc Med May (e-Collection) [REVIEW] (cardiac arrest) (pharmacovigilance / pharmacoepidemiology)
(2025): Sheth PD+, Echocardiography 42(11), e70331 [REVIEW] (chemotherapy-induced cardiotoxicity)
(2025): Si L+, J Am Heart Assoc Dec, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Sugiyama A+, J Pharmacol Exp Ther 392(2), 100023 [REVIEW]
(2024): Chaudhary KW+, Clin Transl Sci 17(12), e70098 [REVIEW]
(2024): Groth O+, MMW Fortschr Med (German) 166(19), 48-51
(2024): Huang Y+, Front Pharmacol Jan (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Lee S+, Eur J Haematol Jun, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2024): Li B+, Arrhythm Electrophysiol Rev 13, e06 [REVIEW]
(2024): Liu L+, Semin Cancer Biol Oct, Online ahead of print [REVIEW]
(2024): Lopez-Medina AI+, Pharmacogenet Genomics Oct, Online ahead of print (pharmacogenomics)
(2024): Mascia G+, J Cardiovasc Med (Hagerstown) 25(11), 775-780 [REVIEW] (Brugada syndrome)
(2024): Simon ST+, PLoS One 19(6), e0303261 [REVIEW] (pharmacogenomics)
(2024): Tan H+, Front Cardiovasc Med May (e-Collection) (pharmacovigilance / pharmacoepidemiology)
(2024): Tetterton-Kellner J+, Adv Drug Deliv Rev Jun, Online ahead of print [REVIEW]
(2024): Woosley RL+, Heart Rhythm 21(6), 969-970 [REVIEW]
(2024): Yan L+, Expert Opin Drug Saf Oct, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2024): Zhong Y+, Expert Opin Drug Saf Oct, Online ahead of print [REVIEW] (association) (pharmacovigilance / pharmacoepidemiology)
(2015): Grossman A+, Eur J Pharmacol 763(Pt A), 15-22 [REVIEW]

Drug-induced disease (Central Nervous System)

(2026): Li X+, Int J Clin Pharm Apr, Online ahead of print [REVIEW] (fever) (pharmacovigilance / pharmacoepidemiology)
(2026): Li Y+, Front Pharmacol Jan (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2026): Lu Z+, Int J Surg 112(2), 2683-2695 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2026): Lv B+, Ther Adv Drug Saf Apr (e-Collection) [REVIEW] (cognitive disorder) (pharmacovigilance / pharmacoepidemiology)
(2026): Maese M+, BMC Res Notes Feb, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2026): Masago S+, In Vivo 40(2), 1220-1227 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2026): Singh MP+, Clin Neuropharmacol 49(1), 11-40 [REVIEW] (aseptic meningitis)
(2026): Xiang X+, Medicine (Baltimore) 105(2), e47076 [REVIEW] (drug-induced depression) (pharmacovigilance / pharmacoepidemiology)
(2025): Alzarea AI+, Front Pain Res (Lausanne) Nov (e-Collection) [REVIEW] (headache) (pharmacovigilance / pharmacoepidemiology)
(2025): An Y+, Front Pharmacol Jul (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Chen Y+, Curr Med Chem Aug, Online ahead of print [REVIEW] (association) (pharmacovigilance / pharmacoepidemiology)
(2025): De Faria Sousa B+, Cureus 17(12), e98340 (drug-Induced parkinsonism)
(2025): Gui J+, Pharmaceuticals (Basel) 18(4), 498 [REVIEW] (pharmacovigilance / pharmacoepidemiology) (pharmacogenomics)
(2025): Kitada S+, Brain Nerve (Japanese) 77(6), 707-713 [REVIEW]
(2025): Kobayashi S+, J Sleep Res Feb, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Liu H+, Int J Surg Jan, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Nic Ionmhain Ú+, Emerg Med Australas 37(3), e70065 [REVIEW] (hyperthermia)
(2025): Ranasinghe P+, Pharmacogenomics Sep, Online ahead of print [REVIEW] (pharmacogenomics)
(2025): Tang L+, Sci Rep 15(1), 21295 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Wang X+, Front Pharmacol Aug (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Wang Y+, Front Neurol Feb (e-Collection) [REVIEW] (insomnia) (pharmacovigilance / pharmacoepidemiology)
(2025): Washist R+, Pediatr Phys Ther 37(1), 57-63 [REVIEW]
(2025): Xu L+, Ther Adv Neurol Disord Jan (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Zhong R+, Expert Opin Drug Saf Apr, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Zou J+, PLoS One 20(10), e0335449 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Althubyani AA+, Drugs Context Jul (e-Collection) [REVIEW]
(2024): Bakewell B+, Front Pharmacol May (e-Collection) (27 cases) [REVIEW]
(2024): Barbosa-Azevedo M+, Toxicol Appl Pharmacol Sep, Online ahead of print [REVIEW]
(2024): Dumont S+, J Sleep Res Sep, Online ahead of print [REVIEW]
(2024): Garg K+, Brain Res Bull Feb (e-Collection) [REVIEW]
(2024): Hu K+, Expert Opin Drug Saf Dec, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2024): Ismail O+, Eur J Clin Pharmacol Jul, Online ahead of print [REVIEW]
(2024): Jia B+, Expert Opin Drug Saf May, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2024): Karatayev O+, Int J Mol Sci 25(15), 8341 [REVIEW]
(2024): Kikegawa M+, Pharmaceuticals (Basel) 17(8), 1099 [REVIEW]
(2024): Preti K+, Clin J Oncol Nurs 28(4), 351-357 [REVIEW]
(2024): Pruett DG+, J Commun Disord Nov, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2024): Rissardo JP+, Medicina (Kaunas) 60(8), 1347 [REVIEW]
(2024): Shah VV+, JCO Precis Oncol 8, e2300312
(2024): Shaia JK+, J Neuroophthalmol Aug, Online ahead of print8%
(2024): Shatunova S+, Eur J Pharmacol Jul, Online ahead of print [REVIEW]
(2024): Sunwoo Y+, Medicina (Kaunas) 60(7), 1028 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Velasco R+, Eur J Neurol Jul, Online ahead of print
(2024): Wang K+, Front Pharmacol Jan (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Wang K+, Front Pharmacol Jan (e-Collection) [REVIEW] (drug-Induced parkinsonism) (pharmacovigilance / pharmacoepidemiology)
(2024): Wang Y+, Expert Opin Drug Saf Dec, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Zhao C+, J Neurol Jun, Online ahead of print [REVIEW]
(2023): Fusaroli M+, Psychiatry Clin Neurosci 77(3), 160-167 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2022): Horseman M+, Cureus 14(7), e27278 [REVIEW]
(2020): Tan MG+, Am J Clin Dermatol 21(2), 163-172 [REVIEW]
(2020): Touafchia D+, Hum Psychopharmacol 35(4), e2734 [REVIEW] (tics) (pharmacovigilance / pharmacoepidemiology)

Drug-induced disease (Endocrine/Metabolic)

(2026): Liu W+, Naunyn Schmiedebergs Arch Pharmacol Apr, Online ahead of print [REVIEW] (hypercalcemia) (pharmacovigilance / pharmacoepidemiology)
(2026): Maese M+, BMC Res Notes Feb, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2026): Xi X+, Pak J Med Sci 42(4), 848-855 [REVIEW] (hyponatremia) (pharmacovigilance / pharmacoepidemiology)
(2026): Zhang P+, Naunyn Schmiedebergs Arch Pharmacol Mar, Online ahead of print [REVIEW] (hypokalemia) (pharmacovigilance / pharmacoepidemiology)
(2026): Zhao X+, Front Med (Lausanne) Jan (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Ben Salem C+, Eur J Intern Med May, Online ahead of print (comment on Mannheimer B+, Eur J Intern Med, May 2025 (loc cit))
(2025): Borsari SF+, Praxis (Bern 1994) (German) 114(4), 149-153 [REVIEW] (adrenal insufficiency)
(2025): Capinha M+, J Clin Med 14(18), 6584 [REVIEW]
(2025): Ide N+, Drug Discov Ther Dec, Online ahead of print [REVIEW] (drug-induced weight gain) (pharmacovigilance / pharmacoepidemiology)
(2025): Li R+, Endocr Pract Dec, Online ahead of print [REVIEW] (thyroid dysfunction) (pharmacovigilance / pharmacoepidemiology)
(2025): Lv H+, Endocr Connect Dec, Online ahead of print [REVIEW] (diabetes insipidus ) (pharmacovigilance / pharmacoepidemiology)
(2025): Mannheimer B+, Eur J Intern Med May, Online ahead of print [REVIEW] (hyponatremia)
(2025): Patel M+, Curr Atheroscler Rep 27(1), 52 [REVIEW]
(2025): Song B+, Expert Opin Drug Saf Feb, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Song B+, BMC Pediatr 25(1), 515 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Xi Y+, Andrology Sep, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Xiao S+, Endocr Metab Immune Disord Drug Targets Aug, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Yang H+, Front Pharmacol Apr (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Yu X+, Diabetol Metab Syndr Oct (e-Collection) [REVIEW] (insulin autoimmune syndrome) (pharmacovigilance / pharmacoepidemiology)
(2025): Zhang H+, Front Endocrinol (Lausanne) Nov (e-Collection) [REVIEW] (association) (pharmacovigilance / pharmacoepidemiology)
(2024): Ji X+, Expert Opin Drug Saf Sep, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2024): Xiao Y+, Magnes Res 38(2), 56-69 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Yang X+, Clin Epidemiol 16, 617-630 (pharmacovigilance / pharmacoepidemiology)
(2012): Deepinder F+, Expert Opin Drug Saf 11(5), 779-95 [REVIEW]

Drug-induced disease (Gastrointestinal/Hepatic)

(2026): Karkra R+, Indian J Gastroenterol Feb, Online ahead of print [REVIEW] (vanishing bile duct syndrome) (pharmacovigilance / pharmacoepidemiology)
(2026): Li H+, Ther Adv Drug Saf Jan (e-Collection) [REVIEW] (drug-induced intestinal obstruction) (pharmacovigilance / pharmacoepidemiology)
(2026): Matilla-Cabello G+, Acta Pharm Sin B 16(6), 3603-3631 (drug-induced liver injury) (pharmacogenomics)
(2026): Minagawa K+, Biol Pharm Bull 49(1), 113-121 [REVIEW] (drug-induced liver injury with eosinophilia) (pharmacovigilance / pharmacoepidemiology)
(2026): Qian Z+, PLoS One 21(6), e0351731 [REVIEW] (gastric motility disorders) (pharmacovigilance / pharmacoepidemiology)
(2026): Wang B+, PLoS One 21(2), e0343209 [REVIEW] ( gastrointestinal bleeding) (pharmacovigilance / pharmacoepidemiology)
(2026): Wang X+, Res Social Adm Pharm May, Online ahead of print [REVIEW] (drug-induced liver injury) (pharmacovigilance / pharmacoepidemiology)
(2026): Zhang Y+, Front Pharmacol Jan (e-Collection) 14% [REVIEW] (drug-induced liver injury)
(2026): Zheng W+, J Int Med Res Mar (e-Collection) [REVIEW] (esophageal ulcer) (pharmacovigilance / pharmacoepidemiology)
(2025): Behrend E+, Rev Med Suisse (French) 21(942), 2201-2202 [REVIEW] (esophagitis)
(2025): Ben Hassine H+, Tunis Med 103(8), 1061-1066 [REVIEW] (pancreatitis) (pharmacovigilance / pharmacoepidemiology)
(2025): Bharathi Rajaduraivelpandian P+, Med Sci (Basel) Dec (e-Collection) [REVIEW] (intestinal angioedema) (pharmacogenomics)
(2025): Daly AK, Liver Int 45(1), e16191 [REVIEW] (liver injury) (pharmacogenomics)
(2025): Di Zeo-Sánchez DE+, Br J Pharmacol Jun, Online ahead of print
(2025): He Y+, Sci Rep Nov (e-Collection) [REVIEW] (drug-induced liver injury) (pharmacovigilance / pharmacoepidemiology)
(2025): Hu Q+, Front Pharmacol May (e-Collection) (drug-induced liver injury)
(2025): Kozielewicz DM+, Clin Exp Hepatol 11(1), 25-33 [REVIEW]
(2025): Li D+, Ann Hepatol Nov, Online ahead of print [REVIEW] (drug-induced liver injury) (pharmacovigilance / pharmacoepidemiology)
(2025): Liu Z+, Curr Oncol 32(7), 393 ("hepatoprotective drugs are not associated with a reduced risk of DILI and may in fact increase risk")
(2025): Maris BR+, Int J Mol Sci 26(5), 2006 [REVIEW]
(2025): Moreno-Torres M+, Biomed Pharmacother Aug, Online ahead of print [REVIEW]
(2025): Nakakuni M+, Pediatr Int 67(1), e15847 (pharmacovigilance / pharmacoepidemiology)
(2025): Olubamiwa AO+, Expert Opin Drug Metab Toxicol Jun, Online ahead of print [REVIEW]
(2025): Olubamiwa AO+, Drug Discov Today Sep, Online ahead of print [REVIEW]
(2025): Sun C+, BMC Pharmacol Toxicol 26(1), 135 [REVIEW] (sinusoidal obstruction syndrome) (pharmacovigilance / pharmacoepidemiology)
(2025): Tchoukeu GLN+, Clin Res Hepatol Gastroenterol Jun, Online ahead of print
(2025): Wang P+, Clin Res Hepatol Gastroenterol Jun, Online ahead of print
(2025): Wei X+, BMC Infect Dis 25(1), 1566 (drug-induced liver injury) (risk factors)
(2025): Wu J+, J Ethnopharmacol Nov, Online ahead of print [REVIEW]
(2025): Xie H+, Front Pharmacol Apr (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Ye W+, PLoS One Feb (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Yu Z+, Arch Toxicol 99(3), 835-850 [REVIEW] (sinusoidal obstruction syndrome)
(2025): Zhang W+, Expert Opin Drug Saf Feb, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Zhu BK+, Sci Rep 15(1), 4783 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Alcorta A+, Pharmacol Ther Jul, Online ahead of print [REVIEW]
(2024): Bessone F+, Clin Gastroenterol Hepatol Jul, Online ahead of print [REVIEW]
(2024): Björnsson ES, Pharmaceuticals (Basel) 17(4), 520 [REVIEW]
(2024): Chen M+, Front Artif Intell Jun (e-Collection)
(2024): Cho FN+, BMC Infect Dis 24(1), 759 (pharmacogenomics)
(2024): Chow R+, Support Care Cancer 32(11), 736 [REVIEW]
(2024): de Castria TB+, Expert Opin Drug Saf Dec, Online ahead of print [REVIEW]
(2024): Domingo-Carnice A+, Med Clin (Barc) Oct, Online ahead of print
(2024): Gao G+, J Hepatol Dec, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2024): Huang Y+, Molecules 29(11), 2663 [REVIEW]
(2024): Li G+, Cell Mol Gastroenterol Hepatol May, Online ahead of print [REVIEW]
(2024): Li W+, Front Pharmacol Sep (e-Collection) (pharmacovigilance / pharmacoepidemiology)
(2024): López-Pascual E+, Int J Mol Sci 25(10), 5203 [REVIEW]
(2024): Ma X+, Clin Ther May, Online ahead of print (Roussel Uclaf Causality Assessment Method)
(2024): Müller SL+, Am J Case Rep 25, e944508 (1 case / male)
(2024): Pan H+, Gut Microbes Dec, Online ahead of print [REVIEW]
(2024): Ravikumar B+, Arch Dis Child Educ Pract Ed May, Online ahead of print [REVIEW]
(2024): Renaux Torres MC+, Support Care Cancer 32(7), 455 [REVIEW]
(2024): Saowapa S+, Proc (Bayl Univ Med Cent) 37(5), 841-850 [REVIEW]
(2024): Suzuki A+, Liver Int Nov, Online ahead of print [REVIEW]
(2024): Wang X+, J Cardiovasc Pharmacol Dec, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2024): Yu S+, Hepatol Int Jun, Online ahead of print
(2024): Zhang G+, Expert Opin Drug Saf Dec, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2023): Andrade RJ+, J Hepatol 79(3), 853-866 [REVIEW]
(2023): Andrade RJ+, J Hepatol 79(3), 853-866 [REVIEW]
(2023): Lee AA+, Pancreatology 23(6), 569-573 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2023): Zhu R+, J Med Microbiol Nov (e-Collection) [REVIEW]
(2022): Tan CK+, World J Gastroenterol 28(24), 2654-2666 [REVIEW]
(1997): Desmet VJ, J Hepatol 26 Suppl 1, 31-5 [REVIEW]

Drug-induced disease (Genitourinary)

(2026): Gong Z+, Front Pharmacol Jan (e-Collection) [REVIEW] (male infertility) (pharmacovigilance / pharmacoepidemiology)
(2026): Jin C+, Medicine (Baltimore) 105(3), e47250 [REVIEW] (drug-induced urinary incontinence ) (pharmacovigilance / pharmacoepidemiology)
(2025): Li C+, Sci Rep 15(1), 38278 (e-Collection) (urinary incontinence) (pharmacovigilance / pharmacoepidemiology)
(2025): Tian X+, Sci Rep 15(1), 15760 [REVIEW] (erectile dysfunction) (pharmacovigilance / pharmacoepidemiology)
(2025): Zheng G+, Sci Rep 15(1), 22856 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Dai X+, Front Pharmacol Jan (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Li D+, Expert Opin Drug Saf Aug, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Moodley D+, Int J Impot Res Dec, Online ahead of print [REVIEW]
(2024): Zheng F+, Expert Opin Drug Saf 23(11), 1419-1426, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2024): Zheng F+, Expert Opin Drug Saf Nov, Online ahead of print (pharmacovigilance / pharmacoepidemiology)

Drug-induced disease (Hair)

(2025): Gaumond SI+, Cancers (Basel) 17(3), 411 [REVIEW]
(2025): Hill RC+, Skin Appendage Disord 11(1), 63-69 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Jia L+, Aesthetic Plast Surg Aug, Online ahead of print [REVIEW]
(2025): Li H+, Front Pharmacol Nov (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Ben Kridis W+, Breast Dis 43(1), 251-255 (72 cases)
(2022): Issa NT+, Dermatol Surg 48(8), 855-861 [REVIEW]

Drug-induced disease (Hematologic)

(2026): Ali SB+, Int Arch Allergy Immunol Mar, Online ahead of print [REVIEW]
(2026): Le BH+, Explor Res Clin Soc Pharm Apr (e-Collection) [REVIEW] (thrombocytopenia) (pharmacovigilance / pharmacoepidemiology)
(2025): Lu Y+, Front Pharmacol Sep (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Wen X+, Int J Clin Pharm 47(3), 755-766 [REVIEW] (hypofibrinogenemia) (pharmacovigilance / pharmacoepidemiology)
(2025): Xia K+, Cancer Control May (e-Collection) [REVIEW] (myelosuppression) (pharmacovigilance / pharmacoepidemiology)
(2025): Yin Y+, Front Pharmacol Sep (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Zhang F+, Int J Clin Pharm 47(6), 1967-1978, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2024): Lu Y+, Front Pharmacol Dec (e-Collection) [REVIEW] (coagulopathy) (pharmacovigilance / pharmacoepidemiology)
(2023): Mazzierli T+, Front Pharmacol Jan (e-Collection) [REVIEW]
(2019): Vo QT+, Ann Pharmacother 53(5), 523-536 [REVIEW] (Naranjo Adverse Drug Reaction Probability Scale or equivalent)

Drug-induced disease (Mucosal)

(2026): Kiattiubolwong T+, Sci Rep May, Online ahead of print (36 cases) (gingival overgrowth) (pharmacogenomics)
(2026): Liu Z+, Int Dent J May, Online ahead of print [REVIEW] (stomatitis) (pharmacovigilance / pharmacoepidemiology)
(2026): Ried PFG+, Naunyn Schmiedebergs Arch Pharmacol Jun, Online ahead of print (gingival overgrowth)
(2026): Wang B+, Int Dent J Jan, Online ahead of print [REVIEW] (drug-induced gingival bleeding) (pharmacovigilance / pharmacoepidemiology)
(2026): Wang X+, Medicine (Baltimore) 105(10), e47844 [REVIEW] (aphthous ulcer) (pharmacovigilance / pharmacoepidemiology)
(2026): Wang X+, Front Pharmacol Mar (e-Collection) [REVIEW] (cheilitis) (pharmacovigilance / pharmacoepidemiology)
(2026): Zhu Q+, Front Pharmacol Apr (e-Collection) [REVIEW] (Gingival hyperplasia/hypertrophy) (pharmacovigilance / pharmacoepidemiology)
(2025): Mao S+, Eur J Pharmacol Aug, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Nodit L+, Sci Data 12(1), 463
(2025): Ostrowska M+, Sci Rep 15(1), 24758
(2025): Ozkeskin SZY+, Adv Pharmacol 104, 447-473 [REVIEW]
(2025): Sportiello L+, Oral Dis 31(3), 993-1005 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Xie C+, Expert Opin Drug Saf Feb, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Zheng H+, Support Care Cancer 33(7), 613 [REVIEW] (oral mucositis )
(2024): Amiri S+, Curr Drug Saf May, Online ahead of print [REVIEW]
(2024): Goel G+, J Cancer Res Ther 20(5), 1564-1569
(2024): Kouri M+, Curr Pain Headache Rep Jul, Online ahead of print [REVIEW]
(2024): Mohan MP+, Support Care Cancer 33(1), 22 (association)
(2024): Xu D+, Heliyon 10(19), e38561 (pharmacovigilance / pharmacoepidemiology)
(2018): Česák T+, Pituitary 21(6), 561-570 [REVIEW] (cerebrospinal fluid rhinorrhea)
(2017): Fortuna G+, Eur J Clin Pharmacol 73(12), 1523-1537 [REVIEW]
(2015): Bascones-Martínez A+, Med Clin (Barc) (Spanish) 144(3), 126-31 [REVIEW]
(2013): Özkaya E, J Am Acad Dermatol 69(2), e51-8 (61 cases)

Drug-induced disease (Multi-Organ / Multi-Metabolic)

(2026): Rai UU+, Int J Risk Saf Med Jun, Online ahead of print [REVIEW]

Drug-induced disease (Nails)

(2026): Xia J+, Cutan Ocul Toxicol Jul, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Trivedi M+, Indian J Dermatol 69(3), 205-211
(2024): Yamamoto K+, Support Care Cancer 32(10), 647

Drug-induced disease (Neuromuscular/Skeletal)

(2026): Akkaya B+, Pediatr Emerg Care Apr, Online ahead of print [REVIEW]
(2026): Chen C+, Health Sci Rep 9(4), e72194 [REVIEW] (dystonia) (pharmacovigilance / pharmacoepidemiology)
(2026): Gao W+, Front Endocrinol (Lausanne) Apr (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2026): Gasser RW+, J Clin Med 15(3), 993 [REVIEW]
(2026): Liu X+, Front Pharmacol Apr (e-Collection) [REVIEW] (osteoporosis) (pharmacovigilance / pharmacoepidemiology)
(2026): Seçilmiş Y+, Eur J Pediatr 185(8), 564 (dystonia)
(2026): Tan W+, Osteoporos Int Mar, Online ahead of print [REVIEW] (osteoporosis)
(2025): Boyne N+, BMC Med Res Methodol 25(1), 33 [REVIEW]
(2025): Liu L+, Front Public Health Jul (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Mellou M+, Therapie Jul, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Nikitina V+, J Clin Med 14(5), 1644 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Rissardo JP+, Medicina (Kaunas) Jan (e-Collection) [REVIEW]
(2025): Sridharan K, Curr Pediatr Rev May, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Wang Y+, Clin Exp Rheumatol Oct, Online ahead of print [REVIEW] (osteoporosis / osteopenia) (pharmacovigilance / pharmacoepidemiology)
(2024): Pitton Rissardo J+, Geriatrics (Basel) 9(4), 100 [REVIEW] (Pisa syndrome)
(2021): Sheikh S+, J Clin Med 10(7), 1537 [REVIEW]
(2017): Guemara R+, Rev Med Suisse (French) 13(562), 1013-1017 [REVIEW]
(2016): Knobloch K, Adv Exp Med Biol 920, 229-38 [REVIEW]

Drug-induced disease (Ocular)

(2026): Cao X+, Front Med (Lausanne) Jan (e-Collection) [REVIEW] (drug-induced cataract) (pharmacovigilance / pharmacoepidemiology)
(2026): Jasti R+, Clin Ophthalmol Feb (e-Collection) [REVIEW] (uveitis)
(2025): Aftab OM+, J Ocul Pharmacol Ther May, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Hong SY+, Sci Rep 15(1), 21341 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Hong SY+, Sci Rep 15(1), 26921 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Khanani I+, Int Ophthalmol Clin 65(1), 3-7 (e-Collection) [REVIEW]
(2025): Leonardi A+, Allergy Sep, Online ahead of print [REVIEW]
(2025): Luboń W+, Int J Mol Sci 26(23), 11744 [REVIEW] (ocular adverse events)
(2025): Vyas C+, Adv Exp Med Biol 1467, 253-262 [REVIEW]
(2025): Xu S+, BMJ Open Ophthalmol 10(1), e002456 [REVIEW] (uveitis) (pharmacovigilance / pharmacoepidemiology)
(2024): Ang T+, Surv Ophthalmol 69(4), 622-631 [REVIEW]
(2024): Cannilla H+, Tremor Other Hyperkinet Mov (N Y) May (e-Collection) [REVIEW]
(2024): Chen XD+, Front Pharmacol Dec (e-Collection) (pharmacovigilance / pharmacoepidemiology)
(2024): Lavasidis G+, Crit Rev Oncol Hematol Jun, Online ahead of print [REVIEW]
(2024): Li L+, Front Endocrinol (Lausanne) May (e-Collection) [REVIEW] (Graves’ ophthalmopathy)
(2024): Pepose JS+, Ophthalmology Sep, Online ahead of print
(2024): Wu SN+, Transl Vis Sci Technol 13(9), 17 (pharmacovigilance / pharmacoepidemiology)
(2023): Hu Y+, Front Endocrinol (Lausanne) May (e-Collection) [REVIEW] (Graves’ ophthalmopathy)
(2022): Sahyoun JY+, BMJ Open Ophthalmol Mar (e-Collection) [REVIEW] (corneal deposits)
(2007): Lachkar Y+, Curr Opin Ophthalmol 18(2), 129-33 [REVIEW]
(2007): Lloyd MJ+, Drugs Today (Barc) 43(11), 827-36 [REVIEW]
(2004): Hollander DA+, Curr Opin Ophthalmol 15(6), 541-8 [REVIEW]

Drug-induced disease (Other)

(2026): Karjalainen K+, Drug Alcohol Rev 45(1), e70083 [REVIEW]
(2026): Qiu Z+, Curr Med Chem Jan, Online ahead of print [REVIEW] (breast cancer) (pharmacovigilance / pharmacoepidemiology)
(2025): Broe A+, Pharmacoepidemiol Drug Saf 34(9), e70211 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Burckart GJ+, Clin Pharmacol Ther Nov, Online ahead of print [REVIEW] (pediatric safety)
(2025): Chen S+, Discov Oncol 16(1), 786 [REVIEW] (drug-induced second tumors) (pharmacovigilance / pharmacoepidemiology)
(2025): Mai H+, J Affect Disord Dec, Online ahead of print [REVIEW] (congenital anomalies) (pharmacogenomics)
(2025): Matthias J+, Clin Transl Sci 18(11), e70406 [REVIEW] (pharmacogenomic interactions) (pharmacogenomics)
(2025): Mellou M+, Therapie Jul, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Rahurkar S+, Pharmacotherapy Oct, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
Negative findings
(2024): Pivato CA+, Eur Heart J Dec, Online ahead of print [REVIEW] ("these findings suggest the cardiovascular safety of fertility treatments")
Negative findings
(2024): Zeng Y+, Andrology Oct, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2023): Montastruc JL, Br J Clin Pharmacol 89(12), 3765-3768 [REVIEW] (bruxism) (pharmacovigilance / pharmacoepidemiology)

Drug-induced disease (Otic)

(2026): Narasimhaswamy N+, Naunyn Schmiedebergs Arch Pharmacol Jun, Online ahead of print [REVIEW] (tinnitus) (pharmacovigilance / pharmacoepidemiology)
(2026): Salvi R+, Hear Res Jul (e-Collection) [REVIEW] (hyperacusis) (pharmacovigilance / pharmacoepidemiology)
(2025): Wu T+, Hear Res Apr, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Li B+, Front Pharmacol Nov (e-Collection) (pharmacovigilance / pharmacoepidemiology)
(2021): Maia NPD+, Int Braz J Urol 47(4), 747-752 [REVIEW]

Drug-induced disease (Renal)

(2025): Ding P+, Front Pharmacol Mar (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Liu W+, Ren Fail Aug (e-Collection) [REVIEW]
(2025): Oliveira CL+, Int J Clin Pharm May, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2024): Connor S+, Toxicol Res (Camb) Aug (e-Collection) [REVIEW]
(2024): Cousin F+, Rev Med Liege (French) 79(5-6), 418-423
(2024): Ganguli A+, J Assoc Physicians India 72(1), 74-80 [REVIEW]
(2024): Garcia G+, Front Med (Lausanne) Oct (e-Collection)
(2024): Joung JY+, Pharmaceuticals (Basel) 17(5), 544 [REVIEW]
(2024): Lyrio RMDC+, Front Nephrol Aug, Online ahead of print [REVIEW]
(2024): Yu CH+, Medicina (Kaunas) 60(8), 1302 [REVIEW]
(2020): Brasselet D+, Expert Opin Drug Saf 19(7), 903-914 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2015): Alberti C, G Chir 36(4), 187-91 [REVIEW]

Drug-induced disease (Respiratory)

(2026): Algabbani AM+, Sci Rep Apr, Online ahead of print [REVIEW] (interstitial lung disease) (pharmacovigilance / pharmacoepidemiology)
(2026): Hu J+, Front Med (Lausanne) Apr (e-Collection) [REVIEW] (eosinophilic pneumonia) (pharmacovigilance / pharmacoepidemiology)
(2026): Poveda JJR+, Pulm Ther Jan, Online ahead of print [REVIEW] (drug-induced interstitial lung disease)
(2026): Rui Y+, J Thorac Dis 18(4), 364 [REVIEW] (pulmonary embolism) (pharmacovigilance / pharmacoepidemiology)
(2026): Zhao Y+, Front Med (Lausanne) Jun (e-Collection) [REVIEW] (acute respiratory distress syndrome ) (pharmacovigilance / pharmacoepidemiology)
(2025): Cui Y+, Respiration Oct, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): He Y+, Sci Rep 15(1), 23937 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Kamath A, Sci Rep 15(1), 1455 (pharmacovigilance / pharmacoepidemiology)
(2025): Rui Y+, Respir Med Sep, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Vanhandsaeme G+, Respiration Nov, Online ahead of print [REVIEW] (drug-induced interstitial lung disease)
(2025): Wang E+, Expert Opin Drug Saf Mar, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Yamanaka M+, Respir Investig 63(4), 524-531 [REVIEW]
(2025): Yayan J+, J Pharm Health Care Sci 11(1), 60 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Zhong Z+, Braz J Med Biol Res Aug (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Annareddy S+, Cureus 16(9), e69954 [REVIEW]
(2024): Butranova OI+, Biomedicines 12(12), 2650 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Cörüt R+, Cureus 16(6), e63408 (20 cases)
(2024): Shen Y+, Int Immunopharmacol Jun, Online ahead of print [REVIEW]
(2024): Shroff GS+, Clin Chest Med 45(2), 325-337 [REVIEW]
(2020): Hayashi R+, Anesth Prog 67(4), 214-218 (1 case / male)

Drug-induced disease (Skin)

(2026): Alharithy R+, Front Med (Lausanne) Apr (e-Collection) 37% [REVIEW]
(2026): Aslan E+, Medicina (Kaunas) 62(4), 711
(2026): Cohen Tervaert JW, Autoimmun Rev Jan (e-Collection) [REVIEW]
(2026): Elmehallawy GS+, Cureus 18(2), e104176 [REVIEW]
(2026): Fetarayani D+, Asia Pac Allergy 16(3), 181-197 [REVIEW] (anaphylaxis)
(2026): Lv X+, J Inflamm Res Feb (e-Collection)
(2026): Yamaguchi M+, Allergol Int Mar, Online ahead of print [REVIEW] (anaphylaxis)
(2025): AlGassim M+, Saudi Pharm J 33(4), 26 [REVIEW]
(2025): Alhaj HA+, Front Pharmacol Sep (e-Collection) [REVIEW] (pharmacogenomics)
(2025): Berges-Gimeno MP+, World Allergy Organ J Sep (e-Collection) [REVIEW] (hypersensitivity reactions)
(2025): Bi J+, Front Pharmacol Oct (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Castellana E+, Hosp Pharm Apr, Online ahead of print [REVIEW] (association) (pharmacovigilance / pharmacoepidemiology)
(2025): Castellana E+, Eur J Hosp Pharm Oct, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Etesami I+, J Skin Cancer Feb (e-Collection) [REVIEW]
(2025): Ge L+, Sci Rep 15(1), 18102 [REVIEW] (photosensitivity) (pharmacovigilance / pharmacoepidemiology)
(2025): Gossell-Williams M+, Int J Risk Saf Med Aug, Online ahead of print [REVIEW]
(2025): Hlavaty A+, Arthritis Rheumatol Nov, Online ahead of print [REVIEW] (Raynaud's phenomenon ) (pharmacovigilance / pharmacoepidemiology)
(2025): Jiamsathit W+, J Clin Med 14(3), 857
(2025): Jiao S+, J Dermatol Nov, Online ahead of print [REVIEW] (severe cutaneous adverse drug reaction) (pharmacovigilance / pharmacoepidemiology)
(2025): Jin Q+, Expert Opin Drug Saf Feb, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Li X+, Arch Dermatol Res 317(1), 647 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Moloudi K+, Biomed J Jul, Online ahead of print [REVIEW]
(2025): Niu Y+, Medicine (Baltimore) 104(37), e44497 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Noguchi Y+, J Eur Acad Dermatol Venereol 39(2), e200-e201 [REVIEW] (Comment on Bataille P+ J. Eur. Acad. Dermatol. Venereol. loc. cit.) (pharmacovigilance / pharmacoepidemiology)
(2025): Qian SY+, J Cutan Med Surg Aug, Online ahead of print [REVIEW]
(2025): Que H+, Clin Cosmet Investig Dermatol 18, 2835-2845 (acute generalized exanthematous pustulosis) (risk factors)
(2025): R Bray E+, J Drugs Dermatol 24(5), 476-481 [REVIEW]
(2025): Roques M+, J Eur Acad Dermatol Venereol May, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Sahu VK+, Bioinformation 21(10), 3461-34645%
(2025): Saldaña Guerrero S+, Cureus 17(7), e87781 (1 case / female) (drug-induced dermatosis (pharmacodermia))
(2025): Shen N+, PLoS One 20(9), e0332079 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Skossyrskiy V+, Med Oncol Dec, Online ahead of print [REVIEW]
(2025): Suffritti C+, J Clin Med 14(16), 5712 [REVIEW]
(2025): Tang J+, Clin Cosmet Investig Dermatol Nov (e-Collection) [REVIEW] (pigmentation, hyperpigmentation and hypopigmentation) (pharmacovigilance / pharmacoepidemiology)
(2025): Tervaert JWC, Autoimmun Rev Nov, Online ahead of print [REVIEW] (anti-neutrophil cytoplasmic antibody (ANCA) vasculitis)
(2025): Wang Z+, Front Immunol Aug (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Xia J+, Front Pharmacol Mar (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Xie Y+, Front Immunol Sep (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Yang Y+, Front Med (Lausanne) Jan (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Bataille P+, J Eur Acad Dermatol Venereol 38(9), 1791-1798 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Brameli A+, J Allergy Clin Immunol Pract Jun, Online ahead of print [REVIEW]
(2024): Bray ER+, Arch Dermatol Res 316(6), 233 (ICI-associated epidermal necrosis should be considered a distinct clinical entity from drug-induced SJS/TEN.)
(2024): Caravan S+, JAMA Dermatol 160(2), 210-217 [REVIEW]
(2024): Chow TG+, Curr Opin Pediatr Aug, Online ahead of print [REVIEW]
(2024): Cole DW+, Am J Dermatopathol 46(6), 337-345
(2024): Fan M+, Front Pharmacol Jul (e-Collection) (pharmacovigilance / pharmacoepidemiology)
(2024): Hung SI+, Nat Rev Dis Primers 10(1), 30 [REVIEW]
(2024): Jiménez-Andrade Y+, Hematol Oncol Clin North Am Jun, Online ahead of print [REVIEW]
(2024): Kemanetzi C+, Dermatol Pract Concept Jul (e-Collection)
(2024): Lu Y+, Front Immunol Jul (e-Collection) (63 cases)
(2024): Rijal H+, J Cutan Med Surg 28(5), 496-497 [REVIEW]
(2024): Samarakoon U+, J Am Acad Dermatol Apr, Online ahead of print
(2024): Temido MJ+, Am J Gastroenterol Oct, Online ahead of print [REVIEW]
(2024): Tetart F+, J Eur Acad Dermatol Venereol Jul [REVIEW]
(2024): Tisack A+, Drugs 84(9), 1071-1091 [REVIEW]
(2024): Ubukata N+, J Am Acad Dermatol May, Online ahead of print [REVIEW]
(2023): Etesami I+, Australas J Dermatol 64(1), 41-49 [REVIEW]
(2023): Parisi R+, Am J Clin Dermatol 24(4), 557-575 [REVIEW]
(2022): Del Pozzo-Magaña BR+, Br J Clin Pharmacol Aug, Online ahead of print [REVIEW]
(2021): Ghaedi F+, Int Immunopharmacol Mar (e-Collection) [REVIEW] (pemphigus)
(2021): Lu JD+, Dermatol Ther 34(1), e14560 [REVIEW] (porokeratosis) (Naranjo Adverse Drug Reaction Probability Scale or equivalent)
(2021): Montastruc JL+, Eur J Clin Pharmacol 77(10), 1587-1588 (pharmacovigilance / pharmacoepidemiology)
(2021): Schuler AM+, J Cutan Pathol 48(12), 1471-1479 [REVIEW]
(2021): Shah N+, Am J Clin Dermatol 22(1), 39-53 [REVIEW]
(2020): Anthony N+, Fundam Clin Pharmacol 34(6), 736-742 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2020): Cohen Aubart F+, J Intern Med 288(3), 356-362 [REVIEW] (sarcoidosis) (pharmacovigilance / pharmacoepidemiology)
(2017): Laurinaviciene R+, Eur J Dermatol 27(1), 28-33 (88 cases)

Litt's app available free to subscribers

Search drug eruptions and reactions data anytime, anywhere